State of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update) – Thematic Intelligence

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Reasons to buy the ‘State of the Biopharmaceutical Industry 2024’ thematic intelligence report:

  • Highlight the business environment and the industry, regulatory, and macroeconomic trends that are going to shape the biopharmaceutical industry in the next 12 months.
  • Benchmark the impact of major themes on the biopharmaceutical industry in the next 12 months,
  • Identify themes that will have the greatest positive or negative impact in the coming months.
  • Comprehend the opinions of industry respondents on these themes.
  • Predict the industry’s growth prospects in the next 12 months.

How is our ‘State of the Biopharmaceutical Industry 2024’ report unique from other reports in the market?

A range of macroeconomic and geopolitical factors, alongside the increasing use of emerging technologies, play a significant role in shaping the current business landscape.  Getting access to the ‘State of the Biopharmaceutical Industry 2024’ thematic intelligence report will help you to:

  • Examine the emerging technologies that will impact the biopharmaceutical industry in the next 12 months.
  • Identify the most impactful, anticipated regulatory approvals and drug launches in the industry in the next 12 months.
  • Gain insight into the regulatory and microeconomics trends that will have positive and negative effects on the biopharmaceutical industry.
  • Identify emerging industry trends and innovations to gain a competitive advantage.

We recommend this valuable source of information to anyone involved in:

  • Pharmaceutical Industry (Big Pharma, Small Biotech, Start-Ups, etc.)
  • Pharmaceutical Industry Suppliers (e.g., Consulting Companies, CMOs, CDMOs, CROs, Technology Vendors)
  • Professional Services (e.g., Investment Companies, Investment Banks, etc.)
  • Biotech
  • Consulting Companies
  • Technology Companies and Start-ups

To Get a Snapshot of the State of the Biopharmaceutical Industry Thematic Report
Download a Free Report Sample

State of the Biopharmaceutical Industry 2024 – Thematic Report Overview

A range of macroeconomic and geopolitical factors, alongside the increasing use of emerging technologies, play a significant role in shaping the current biopharmaceutical business landscape. The adoption of technologies can offer potential solutions to operational and efficiency challenges in the industry. While technological advancements can offer solutions to operational and efficiency challenges, businesses need to contend with ongoing supply-demand imbalance, unsettled inflationary pressures, recession prospects, market volatility, geopolitical tensions, and conflicts.

In this “The State of the Biopharmaceutical Industry” report, GlobalData examines the business environment and trends that are going to shape the biopharmaceutical industry in the next 12 months.

  • The biopharmaceutical industry’s optimism regarding growth in the next 12 months is on the rise, but still below the levels seen in 2022.
  • A total of 56% of survey respondents shared optimistic or very optimistic sentiments on the biotech funding recovery in 2024.
  • The top-rated industry trends anticipated for the next 12 months include anti-obesity medications, personalized/precision medicine, immuno-oncology drug development, real-world evidence, and cell and gene therapies.
  • Anti-obesity medications were identified as the emerging pharmaceutical industry trend to have the greatest impact in 2024.
  • From macro and regulatory trends, vertical integration, drug pricing and reimbursement pressures, and patent expiration of biologics are expected to have the greatest positive impact on the pharmaceutical industry.
  • Geopolitical conflicts and drug pricing and reimbursement pressures will be the main hindrances to pharmaceutical sector growth.
  • Pharmaceutical companies will keep a close watch on both the BIOSECURE Act and EU Pharmaceutical Reform.
  • The Inflation Reduction Act is believed to make government price negotiation more likely across all pharmaceuticals.
  • Donanemab for Alzheimer’s disease is poised for major commercial success in the 2024 launches.
  • Oncology, central nervous system, and infectious diseases are the dominant areas for clinical trials initiated in 2023.
  • Oncology dominates the therapy landscape in 2024, but metabolic disorders display the highest growth.
  • Big data and artificial intelligence will continue to dominate as transformational forces in the healthcare sector in the next 12 months.
Key Emerging Trends ·       Anti-Obesity Medications

·       Personalized/Precision Medicine

·       Immuno-Oncology Drug Development

·       Real-World Evidence

·       Cell and Gene Therapies

Key Emerging Technologies ·       AI

·       Big Data

·       Cybersecurity

·       Internet of Things

·       Digital Media

·       Social Media

·       Virtual and Augmented Reality

Key Therapy Areas ·       Oncology

·       Metabolic Disorders

·       Immunology

·       Infectious Disease

·       Central Nervous System

Key Industry Sponsors ·       Novartis

·       Pfizer

·       Johnson & Johnson (J&J)

·       Takeda Pharmaceutical

·       AbbVie

Enquire and Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before purchasing.

Biopharmaceutical Industry - Emerging Trends

The emerging industry trends that will shape the biopharmaceutical industry in the next 12 months are anti-obesity medications, personalized/precision medicine, immuno-oncology drug development, real-world evidence, and cell and gene therapies, among others. Anti-obesity medications have been identified as the top emerging pharmaceutical industry trend for 2024.

Obesity is a complex condition that presents significant health risks, such as cardiovascular diseases or diabetes. Hence, the development of anti-obesity medications is currently revolutionizing the biopharmaceutical market. They represent a promising avenue to address this widespread global epidemic.

Most Impactful Industry Trends on the Pharmaceutical Industry, 2024

Most Impactful Industry Trends on the Pharmaceutical Industry, 2024

Buy the Full Report for More Emerging Trend Insights in the Biopharmaceutical Industry

Download a Free Report Sample

Emerging Technologies in the Biopharmaceutical Industry

The most disruptive emerging technologies that will influence the biopharmaceutical industry in the next 12 months are AI, big data, cybersecurity, the Internet of Things (IoT), digital media, social media, and virtual and augmented reality, among others. Across all geographies, AI and big data are expected to garner the highest impact on the pharmaceutical industry in the next 12 months.

Across all geographies, AI and big data are expected to have the biggest impact on the pharmaceutical industry in the coming months. AI and big data are complementary technologies as AI algorithms can facilitate processing, analysis, and insight extraction from the data pools. Proficiency in these areas is essential for the healthcare industry as it can enhance patient care at a micro level and, more broadly, yield a higher level of insights and trends that drive operational and clinical efficiency.

Most Disruptive Emerging Technology in the Pharmaceutical Sector, 2024

Most Disruptive Emerging Technology in the Pharmaceutical Sector, 2024

Buy the Full Report for More Insights on Emerging Technologies in the Biopharmaceutical Industry

Download a Free Report Sample

Therapy Areas in the Biopharmaceutical Industry

The top therapy areas in the biopharmaceutical industry are oncology, metabolic disorders, immunology, infectious disease, and central nervous system, among others. Oncology remains the single largest therapy area in H2 2024.

Top 10 Therapy Areas – 2023 Vs 2024

Top 10 Therapy Areas – 2023 Vs 2024

Buy the Full Report for More Therapy Area Insights on the Biopharmaceutical Industry

Download a Free Report Sample

Biopharmaceutical Industry – Competitive Landscape

Top industry sponsors for planned clinical trials in 2024 include Novartis, Pfizer, Johnson & Johnson (J&J), Takeda Pharmaceutical, and AbbVie, among others. AstraZeneca, Novartis, and J&J will likely complete the most industry trials in 2024.

Buy the Full Report for More Insights on Sponsors in the Biopharmaceutical Industry

Download a Free Report Sample

Segments Covered in the Report

Biopharmaceutical Industry Emerging Technologies Outlook (2024)

  • AI
  • Big Data
  • Cybersecurity
  • Internet of Things
  • Digital Media
  • Social Media
  • Virtual and Augmented Reality

Biopharmaceutical Industry Therapy Area Outlook (2024)

  • Oncology
  • Metabolic Disorders
  • Immunology
  • Infectious Disease
  • Central Nervous System

Key Highlights

– Optimism is rising about pharmaceutical industry growth in the next 12 months.

– Anti-obesity medications will take center stage.

– Geopolitical conflicts, as well as drug pricing and reimbursement-related concerns, will impede industry growth.

– Vertical integration, drug pricing and reimbursement constraints, and biologics’ patent expiry will have the most positive impacts on industry.

– AI is positioned to bring disruptive change to the pharmaceutical industry.

– Biotech funding continues to show signs of recovery after its post-COVID-19 pandemic decline.

AbbVie
Accord Healthcare
Actinium Pharmaceuticals
Adaptimmune Therapeutics
Aetna
Akeso
Almac
Altor Bioscience
Alvotech
Amazon
Amgen
Amylyx Pharmaceuticals
Astellas Pharma
AstraZeneca
Autolus Therapeutics
Biocon Biologics
Biogen
BioNTech
Bio-Thera Solutions
Boehringer Ingelheim
BridgeBio Pharma
Bristol Myers Squibb
Catalent
CeleCor Therapeutics
Celltrion
Chia Tai Tianqing Pharmaceutical
Cigna
CVS Health
Daiichi Sankyo
Day One Biopharmaceuticals
Dr. Reddy's Laboratories
Eli Lilly
Express Scripts
F. Hoffmann-La Roche
Ferring Pharma
Formycon
Fresenius Kabi
Fuji Pharma
Genmab
Geron Corp
Gilead
IASO Bio
Incyte
Intas Pharmaceuticals
Iovance
Janssen
Jazz Pharmaceuticals
Johnson & Johnson
Karuna Therapeutics
Lantheus Holdings
Merck & Co
Merus NV
Mochida Pharmaceutical
Moderna
Mylan
Novartis
Novo Nordisk
Ono Pharmaceuticals
Optum
Optum-Amedisys
Pfizer
Qilu Pharmaceutical
Regeneron
RemeGen
Roche
Samsung Bioepis
Sandoz
Seagen
Seres Therapeutic
Sichuan Kelun Pharmaceutical
STgen Bio
Strides Pharma Science
Syndax Pharmaceuticals
Thermo Fisher
UnitedHealth
Verona Pharma
Vetter
Viatris
WuXi
Xaira Therapeutics

Table of Contents

1. Executive Summary

2. Study Design

3. Emerging Industry Trends

4. Emerging Regulatory and Macroeconomic Trends

5. Emerging Technologies

6. Industry’s Growth Prospects

7. Watch Outs

8. Summary of Key Findings

9. Appendix

10. Authors and Contributors

11. Contact Us

Frequently asked questions

State of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update) – Thematic Intelligence thematic reports
Currency USD
$1,950

Can be used by individual purchaser only

$3,900

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

State of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update) – Thematic Intelligence was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
5-Hydroxytryptamine Receptor 2A - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
Mu Type Opioid Receptor - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
GTPase KRas - Drugs In Development, 2024
$3,500 | June 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at State of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update) – Thematic Intelligence in real time.

  • Access a live State of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update) – Thematic Intelligence dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.